ReviewThe American journal on addictions2016
A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.
Review in The American journal on addictions, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.The American journal on addictions · 2021Trial
- State Proposed Strategies to Expand Access to Medications for Opioid Use Disorder.Health services research · 2026Article
- Implementation and outcomes of a multifaceted care model for people experiencing homelessness and people who inject drugs hospitalized with complicated infections.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Naloxone Dispensing to Youth Ages 10-19: 2017-2022.Pediatrics · 2024Article
- Exploring Opioid Prescription Patterns and Overdose Rates in South Carolina (2017-2021): Insights into Rising Deaths in High-Risk Areas.Healthcare (Basel, Switzerland) · 2024Article
- Prescriptions for Buprenorphine in Michigan Following an Education Intervention.JAMA network open · 2023Article
- Preceptors' preparedness to teach about substance and opioid use disorder: a qualitative study.BMC medical education · 2022Article
- Educating the community about the opioid epidemic and medications for opioid use disorder.The American journal on addictions · 2022Article
- How Physician Workforce Shortages Are Hampering the Response to the Opioid Crisis.Psychiatric services (Washington, D.C.) · 2022Article
- Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study.The Journal of clinical psychiatry · 2022Article
- Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.Substance abuse · 2022Article
- "It's way more than just writing a prescription": A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder.Addiction science & clinical practice · 2021Article
- "Now We Are Seeing the Tides Wash In": Trauma and the Opioid Epidemic in Rural Appalachian Ohio.Substance use & misuse · 2021Article
- Program development and implementation outcomes of a statewide addiction consultation service: Maryland Addiction Consultation Service (MACS).Substance abuse · 2021Article
- Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2020Article
- Been There, Done That: Lessons from Vancouver's Efforts to Stem the Tide of Overdose Deaths.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020Article
- Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.The American journal of psychiatry · 2020Article
- Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review.BMC family practice · 2019Review
- Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome.Epidemiology (Cambridge, Mass.) · 2018Article
- Feasibility of implementing a screening tool for risk of opioid misuse in a trauma surgical population.Implementation research and practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesThe Providers' Clinical Support System for Medication Assisted Treatment (PCSS-MAT) initiative focuses on training and mentoring health professionals in the treatment of opioid use disorders (OUD) using pharmacological strategies. Led by the American Academy of Addiction Psychiatry (AAAP), PCSS-MAT is a consortium representing four of the five national professional organizations authorized by DATA 2,000-AAAP, American Osteopathic Academy of Addiction Medicine, American Psychiatric Association, and American Society of Addiction Medicine. DATA organizations are authorized to train physicians to prescribe buprenorphine for OUD treatment. The primary aim of PCSS-MAT is to substantially increase evidence-based practices with medications for OUD.
methodsThis review describes the development of PCSS-MAT, an ongoing national initiative funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), to address the training needs posed by this critical public health problem. Core initiatives include: (1) Training and mentoring activities for primary care physicians; (2) Outreach to multidisciplinary professional organizations, (3) Creating a resource portal for families, patients, and communities for OUD treatment.
resultsEducational outreach to providers addresses the needs of patients with OUD and common co-occurring psychiatric and medical disorders. DISCUSSION AND
conclusionsThe overall scope of PCSS-MAT is to increase access to evidence-based treatment of substance use disorders as a public health priority. Recently enacted legislation requires office-based opioid treatment programs to offer all Food and Drug Administration-approved (FDA) forms of MAT. SCIENTIFIC SIGNIFICANCE: Working with health care providers to effectively deliver MAT is key to integrating behavioral and physical medicine. (Am J Addict 2016;25:603-609).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.